Advanced Tumor Organoid & CAF Co-culture Service To Accelerate Cancer Research

CD Bioparticles, a leading manufacturer and supplier of numerous drug delivery products and services, has announced the launch of its new Tumor Organoid & CAF Co-culture services to provide researchers with a more physiologically relevant in vitro tumor model, enabling a deeper understanding of tumor-stromal interactions and the development of more effective cancer therapies.

Although cancer originates from mutations accumulating within cancer cells, disease progression and treatment response are both strongly regulated by non-mutated cells within the tumour microenvironment. Significant advances have been made in recent years in the study of cancer-associated fibroblasts (CAFs). These cells regulate cancer metastasis by synthesizing and remodelling the extracellular matrix (ECM), as well as secreting growth factors. They also influence angiogenesis, tumour mechanical properties, drug access and therapeutic response. Recent studies have also revealed CAFs’ crucial role in modulating the immune system. Targeting intervention by altering CAF numbers, subtypes or functional characteristics is emerging as a novel approach to enhancing the efficacy of cancer treatment. However, this field faces multiple challenges, particularly due to the dual pro-tumour and anti-tumour effects of CAFs.

While traditional organoid models can replicate tumour epithelial structures, they lack stromal support, which makes it difficult to fully capture the complexity of tumour behaviour within the native microenvironment. Co-culturing CAFs with tumour organoids enables a more precise reconstruction of the tumour microenvironment and helps to elucidate tumour-stromal interactions. This co-culture system also simulates tumour heterogeneity and evolutionary processes, providing an ideal platform for investigating CAF-mediated drug resistance, immune suppression and barriers to efficient drug delivery.

CD Bioparticles now offers comprehensive co-culture services for tumour organoids and CAFs, enabling researchers to construct more precise and dynamic in vitro tumour models. By co-culturing patient-derived tumour organoids with CAFs, CD Bioparticles can help to preserve the intricate interactions between tumours and their stroma. The company also provides flexible options for CAF sources, including cells isolated from tumour tissues, client-provided cells, or commercially available cell lines. For more complex models, the system can be expanded to allow the optional integration of immune or endothelial cells, creating multi-cellular 3D microenvironments. This comprehensive approach is complemented by multidimensional evaluation using functional assays, transcriptomics and imaging analyses to determine the full impact of CAFs on tumour behaviour.

By more accurately mimicking the in vivo tumour microenvironment, CD Bioparticles’ Organoid & CAF co-culture models can provide valuable insights into important processes such as tumour progression, immune evasion, therapeutic resistance and the efficacy of drug delivery. Consequently, this technology serves as a physiologically relevant in vitro tool that advances tumour biology research and significantly enhances the predictive accuracy of drug screening and delivery assessment platforms.

To know more information about these Tumor Organoid & CAF Co-culture services and solutions for cancer therapy development, please visit https://www.cd-bioparticles.net/services/tumor-organoid-caf-co-culture-service.html.

About CD Bioparticles

CD Bioparticles is an established drug delivery company that provides customized solutions for developing and manufacturing novel biocompatible drug delivery systems. It specializes in various formulation and drug delivery technologies, from conventional liposomes and PEGylated liposomes to polymer microspheres and nanoparticles for drug delivery. The company also provides contract research services for drug delivery formulation, formulation feasibility study, process development and scale-up, as well as analytical and non-clinical research services.